References
- 1. AHIRWAR AK., JAIN A., GOSWAMI B., BHATNAGAR MK., BHATACHARJEE J. Imbalance between protective (adiponectin) and prothrombotic (Plasminogen Activator Inhibitor-1) adipokines in metabolic syndrome. Diab Met Syndr: Clin Res Rev. 2014; 8 (3):152-5.
- 2. ALBERTI G., ZIMMET P., SHAW J., GRUNDY SM. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: International Diabetes Federation. 2006 Nov 8:1-23.
- 3. MOZUMDAR A., LIGUORI G. Persistent increase of prevalence of metabolic syndrome among US adults: NHANES III to NHANES 1999–2006. Diabetes Care. 2011 Jan 1; 34 (1):216-9.
- 4. PRASAD DS., KABIR Z., DASH AK., DAS BC. Prevalence and risk factors for metabolic syndrome in Asian Indians: A community study from urban Eastern India. Journal of cardiovascular disease research. 2012 Sep 30; 3 (3):204-11.
- 5. TZIOMALOS K., ATHYROS VG., KARAGIANNIS A., MIKHAILIDIS DP. Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. Nutrition, Metabolism and Cardiovascular Diseases. 2010 Feb 28; 20 (2):140-6.10.1016/j.numecd.2009.08.006
- 6. HADI HA., CARR CS., SUWAIDI JA. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vascular health and risk management. 2005 Sep; 1 (3):183.
- 7. NIKNAM N., KHALILI N., KHOSRAVI E., NOURBAKHSH M. Endothelial dysfunction in patients with subclinical hypothyroidism and the effects of treatment with levothyroxine. Advanced biomedical research. 2016; 5.
- 8. MATHEW F., GLENDA J., JACK L. Quantification of nitric and nitrate in extracellular fluids. Metho Enzymol 1996; 268:237-46.
- 9. La Vignera S., Condorelli R., Vicari E., Calogero AE. Endothelial dysfunction and subclinical hypothyroidism: A brief review. J Endocrinol Invest. 2012; 35 (1): 96-103.
- 10. CABRAL MD., TEIXEIRA P., SOARES D., LEITE S., SALLES E., WAISMAN M. Effects of thyroxine replacement on endothelial function and carotid artery intima-media thickness in female patients with mild subclinical hypothyroidism. Clinics. 2011; 66 (8):1321-8.
- 11. AHIRWAR AK., JAIN A., SINGH A., GOSWAMI B., BHATNAGAR MK., BHATACHARJEE J. The study of markers of endothelial dysfunction in metabolic syndrome. Horm Mol Biol Clin Invest. 2015; 24 (3):131-6.
- 12. BALZAN S., DEL CARRATORE R., NICOLINI G., BEFFY P., LUBRANO V., FORINI F et al. Proangiogenic effect of TSH in human microvascular endothelial cells through its membrane receptor. The Journal of Clinical Endocrinology & Metabolism. 2012 Mar 14; 97 (5):1763-70.
- 13. MEHRAN L., AMOUZEGAR A., RAHIMABAD PK., TOHIDI M., TAHMASEBINEJAD Z., AZIZI F. Thyroid Function and Metabolic Syndrome: A Population-Based Thyroid Study. Hormone and Metabolic Research. 2017 Mar; 49 (03):192-200.
- 14. TIAN L., ZHANG L., LIU J., GUO T., GAO C., NI J. Effects of TSH on the function of human umbilical vein endothelial cells. Journal of molecular endocrinology. 2014 Apr 1; 52 (2):215-22.
- 15. TÜREMEN EE., ÇETINARSLAN B., SAHIN T., CANTÜRK Z., TARKUN I. Endothelial dysfunction and low grade chronic inflammation in subclinical hypothyroidism due to autoimmune thyroiditis. Endocrine journal. 2011; 58 (5):349-54.10.1507/endocrj.K10E-333
- 16. DARDANO A., GHIADONI L., PLANTINGA Y., CARACCIO N., BEMI A., DURANTI E et al. Recombinant human thyrotropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism. 2006 Oct; 91 (10):4175-8.
- 17. ITO A., TSAO PS., ADIMOOLAM S., KIMOTO M., OGAWA T., COOKE JP. Novel mechanism for endothelial dysfunction. Circulation. 1999 Jun 22; 99 (24):3092-5.
- 18. NOFER JR., VAN DER GIET M., TÖLLE M., WOLINSKA I., VON WNUCK LIPINSKI K., BABA HA. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P 3. The Journal of clinical investigation. 2004 Feb 15; 113 (4):569-81.